A carregar cotações...
Previsão
O preço-alvo médio dos analistas é € 19,07 (+390,23%). A mediana é € 19,07 (+390,23%).
| Comprar |
2 |
| Manter |
5 |
| Vender |
1 |
Discussões na comunidade
- Delisting Curevac
Hallo, ich hatte nicht mitbekommen , dass ich selbst aktiv werden musste um meine Curevac Aktien gegen Biontec zu tauschen. Es kam von TRADE REPUBLIC auch kein Hinweis. Gestern dann bekam ich diese…
WW Wolf W. II em Schnack
0 6 - TTWROR negativ bei erfolgreichem Invest und Laufzeit von zwei Monaten
Ich habe versucht einen älteren Post dafür zu nutzen, habe aber gemerkt, dass der Thread nicht wieder oben angezeigt wird… deswegen ein neues Thema. Ich stehe in dieser Sache gerade auf dem…
RP910 IV em Schnack
0 4
Notícias Ir para o feed de notícias
Curevac closure threatens hundreds of job losses in Tübingen
After the announcement to close the Curevac site, hundreds of employees face deep cuts; the works council expects about two-thirds of jobs to disappear by the end of 2026 and says operational activity is to be stopped on December 31. A taskforce appointed by the state government aims to secure infrastructure and know-how and to offer staff prospects, while Biontech emphasizes a socially acceptable reduction of personnel and support programs. The works council criticizes the management’s limited willingness to negotiate and points out that there are hardly any comparable jobs in the region for highly specialized professionals. » Mais em finanzen.net
Curevac founder accuses Biontech of deception after announced factory closures
Ingmar Hoerr sharply criticizes Biontech and calls the takeover of Curevac a "dumb sale", saying that, according to him, jobs are to be cut and production sites in Marburg, Idar‑Oberstein, Singapore and Tübingen are to be closed. He accuses Biontech of using the takeover primarily to acquire patents and to eliminate a competitor. Hoerr warns that knowledge built up over decades will be lost and at the same time criticizes Biontech's share buyback program as contradictory to the stated reasons for cost cutting. » Mais em welt.de
Curevac founder accuses Biontech of deception after announced site closures
After the takeover of Curevac, founder Ingmar Hoerr accuses Biontech of deception after Biontech announced the closure of several sites, including Tübingen. Around 820 former Curevac employees are affected; up to 1,860 positions could be cut across the group. Biontech justifies the measures with overcapacity and cost reductions, while the union and Tübingen’s mayor sharply criticize and speculate about patent strategies and the prioritization of financial interests. » Mais em faz.net
CureVac founder accuses BioNTech of deception after takeover and plant closures
After BioNTech's takeover of CureVac, founder Ingmar Hoerr criticizes the company over planned closures, particularly the Tübingen site, calling it deception and suggesting possible circumvention of patent disputes. BioNTech justifies the closures with excess capacity, low utilization and cost cutting; up to 1,860 jobs could be affected worldwide. Unions describe the move as socially irresponsible, while BioNTech simultaneously announces a multi-billion euro share buyback program; the stock fell in response. » Mais em finanzen.net
Curevac sues Moderna over patent infringement on mRNA technology
Curevac filed a lawsuit against Moderna in a U.S. federal court in Delaware, accusing the company of infringing several Curevac patents used to stabilize mRNA in its COVID-19 vaccine Spikevax. The Tübingen-based company is seeking damages in the form of licensing fees on Spikevax sales and has named eight U.S. patents. Curevac was acquired by Biontech last year; Biontech is pursuing its own separate lawsuit against Moderna. Moderna said it intends to defend itself vigorously. » Mais em manager-magazin.de
Dados financeiros da empresa
| (EUR) | setembro de 2025 | YoY |
|---|---|---|
| Receitas | 54,13 mi | - |
| Ganho bruto | 53,76 mi | - |
| Ganho líquido | 273,23 mi | - |
| EBITDA | 317,86 mi | - |
Dados fundamentais
| Métrica | Valor |
|---|---|
Capitalização bolsista | € 952,7 mi |
Número de ações | 225,17 mi |
Máximo/mínimo de 52 semanas | € 5,19 - € 2,25 |
| Dividendos | Não |
Beta | 1,84 |
PER (PE Ratio) | 4,45 |
PEG (PEG Ratio) | 0,32 |
P/VC (PB Ratio) | 1,09 |
P/V (PS Ratio) | 17,19 |
Perfil da empresa
A CureVac N.V., uma empresa biofarmacêutica em fase de ensaios clínicos, dedica-se ao desenvolvimento de diversos medicamentos transformadores baseados no ácido ribonucleico mensageiro (mRNA). Está a desenvolver vacinas profiláticas, como os candidatos a vacina baseados em mRNA CV2CoV, que se encontra em ensaio clínico de Fase 1 contra o SARS-CoV-2; a CV7202, uma vacina profilática baseada em mRNA, que concluiu o ensaio clínico de Fase 1 para a glicoproteína do vírus da raiva; e a CVSQIV, que se encontra em ensaio clínico de Fase 1 contra a gripe, bem como uma vacina contra a febre de Lassa, a febre-amarela, o vírus sincicial respiratório, o rotavírus, a malária e a gripe universal. A empresa desenvolve também imunoterapias contra o cancro baseadas em RNA, incluindo a CV8102, que se encontra em ensaio clínico de Fase 1 para o tratamento de melanoma cutâneo e de carcinoma adenoide cístico, bem como de carcinoma de células escamosas da pele, da cabeça e do pescoço. A empresa foi fundada em 2000 e tem sede em Tübingen, na Alemanha.
| Nome | CureVac |
| CEO | Alexander Zehnder |
| Sede | Tübingen,
Países Baixos |
| Site | |
| Setor | Cuidados de saúde |
| Indústria | Biotecnologia |
| Entrada em bolsa | 14/08/2020 |
| Colaboradores | 825 |
Símbolos de ticker
| Bolsa | Símbolo |
|---|---|
NASDAQ | CVAC |
XETRA | 5CV.F |
XETRA | 5CV.DE |
Frankfurt | 5CV.F |
Düsseldorf | 5CV.DU |
Hamburg | 5CV.HM |
Milan | 1CVAC.MI |
London | 0A9E.L |
SIX | 5CV.SW |
München | 5CV.MU |
Wien | CVAC.VI |